$TSVT
2seventy bio, Inc. Stock $tsvt

$tsvt Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000186078222000026 Filed on May 12, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$13.48M	$8.429M	$16.03M
YoY Change	-29.89%	-29.17%	-93.54%
Cost Of Revenue	$364.0K	$511.0K	$406.0K
YoY Change	-79.68%	-70.01%	-92.48%
Gross Profit	$13.12M	$7.918M	$15.63M
YoY Change	-24.77%	-22.35%	-93.56%
Gross Profit Margin	97.3%	93.94%	97.47%
Selling, General & Admin	$17.28M	$23.86M	$24.48M
YoY Change	-62.46%	-3.11%	-73.07%
% of Gross Profit	131.71%	301.35%	156.65%
Research & Development	$68.44M	$69.25M	$59.54M
YoY Change	-51.55%	-10.73%	-79.92%
% of Gross Profit	521.72%	874.53%	381.0%
Depreciation & Amortization	$3.301M	$3.530M	$3.535M
YoY Change	-59.49%	-3.97%	-46.9%
% of Gross Profit	25.16%	44.58%	22.62%
Operating Expenses	$85.80M	$93.11M	$84.00M
YoY Change	-54.29%	-8.9%	-77.95%
Operating Profit	-$72.68M	-$90.59M	-$68.37M
YoY Change	-57.31%	-1.93%	-50.52%
Interest Expense	$213.0K	$115.0K	$88.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$644.0K	$4.762M	$7.307M
YoY Change	-107.07%	-7.96%	-59.53%
Pretax Income	-$77.40M	-$85.71M	-$60.98M
YoY Change	-54.8%	-1.7%	-49.23%
Income Tax	$17.00K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$77.42M	-$85.70M	-$60.98M
YoY Change	-54.79%	-1.72%	-49.23%
Net Earnings / Revenue	-574.25%	-1016.73%	-380.29%
Basic Earnings Per Share	-$2.02	-$3.20
Diluted Earnings Per Share	-$2.017M	-$3.20	-$2.552M
COMMON SHARES
Basic Shares Outstanding	37.62M shares	26.75M shares	23.37M shares
Diluted Shares Outstanding	38.38M shares	26.75M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$357.9M	$377.9M	$265.1M
YoY Change
Cash & Equivalents	$269.9M	$270.9M	$130.4M
Short-Term Investments	$88.06M	$107.0M	$134.6M
Other Short-Term Assets	$13.80M	$18.00M	$9.512M
YoY Change	90.24%
Inventory
Prepaid Expenses		$18.00M	$9.512M
Receivables	$12.16M	$16.93M	$17.00M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$383.9M	$412.8M	$291.6M
YoY Change	1961.15%		1061.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$304.1M	$35.04M	$34.91M
YoY Change	19.77%		-75.76%
Goodwill		$12.06M	$12.06M
YoY Change			-8.17%
Intangibles		$8.774M	$9.892M
YoY Change			75.27%
Long-Term Investments	$40.64M	$74.68M	$97.12M
YoY Change
Other Assets	$39.03M	$37.75M	$38.59M
YoY Change	559.22%		367.05%
Total Long-Term Assets	$403.5M	$439.1M	$468.1M
YoY Change	41.53%		62.81%
TOTAL ASSETS
Total Short-Term Assets	$383.9M	$412.8M	$291.6M
Total Long-Term Assets	$403.5M	$439.1M	$468.1M
Total Assets	$787.4M	$851.9M	$759.7M
YoY Change	159.23%		143.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.685M	$13.65M	$6.024M
YoY Change	-64.78%		-15.77%
Accrued Expenses	$79.81M	$68.54M	$65.18M
YoY Change	5.4%
Deferred Revenue		$5.000M	$5.000M
YoY Change			509.76%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$99.01M	$106.3M	$98.39M
YoY Change	-4.6%		29.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$309.4M	$2.431M	$2.122M
YoY Change	104.54%		-14.78%
Total Long-Term Liabilities	$309.4M	$2.431M	$2.122M
YoY Change	104.54%		-14.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$99.01M	$106.3M	$98.39M
Total Long-Term Liabilities	$309.4M	$2.431M	$2.122M
Total Liabilities	$408.4M	$404.5M	$399.9M
YoY Change	60.13%		68.01%
SHAREHOLDERS EQUITY
Retained Earnings		-$125.2M	-$39.49M
YoY Change
Common Stock		$4.000K	$2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$379.0M	$447.4M	$359.8M
YoY Change
Total Liabilities & Shareholders Equity	$787.4M	$851.9M	$759.7M
YoY Change	159.23%		143.0%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$77.42M	-$85.70M	-$60.98M
YoY Change	-54.79%	-1.72%	-49.23%
Depreciation, Depletion And Amortization	$3.301M	$3.530M	$3.535M
YoY Change	-59.49%	-3.97%	-46.9%
Cash From Operating Activities	-$46.66M	-$74.10M	-$57.44M
YoY Change	-56.08%	14.44%	-50.8%
INVESTING ACTIVITIES
Capital Expenditures	-$2.673M	$3.585M	-$975.0K
YoY Change	-73.21%	-43.55%	-90.86%
Acquisitions
YoY Change
Other Investing Activities	$52.44M	$48.33M	$34.99M
YoY Change
Cash From Investing Activities	$49.77M	$44.75M	$34.01M
YoY Change	-598.9%	-804.6%	-418.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-4.277M	$170.1M	186.7M
YoY Change	-103.68%	139.24%	46.53%
NET CHANGE
Cash From Operating Activities	-46.66M	-$74.10M	-57.44M
Cash From Investing Activities	49.77M	$44.75M	34.01M
Cash From Financing Activities	-4.277M	$170.1M	186.7M
Net Change In Cash	-1.168M	$140.8M	163.3M
YoY Change
FREE CASH FLOW
Cash From Operating Activities	-$46.66M	-$74.10M	-$57.44M
Capital Expenditures	-$2.673M	$3.585M	-$975.0K
Free Cash Flow	-$43.99M	-$77.69M	-$56.46M
YoY Change	-54.31%	9.26%	-46.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001860782
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	tsvt	Common Stock Convertible Conversion Ratio CommonStockConvertibleConversionRatio	0.3333
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-40791
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	2seventy bio, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-3658454
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	60 Binney Street
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	2142
CY2022Q1	dei	City Area Code CityAreaCode	339
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	499-9300
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	TSVT
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37622368	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	270893000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130414000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	106973000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	134643000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	18002000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9512000	USD
CY2022Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	16931000	USD
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	16995000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	412799000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	291564000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35038000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34913000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	74683000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	97124000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8774000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9892000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	12056000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	12056000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	270825000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	275534000	USD
CY2022Q1	tsvt	Restricted Cash And Other Assets Noncurrent RestrictedCashAndOtherAssetsNoncurrent	37746000	USD
CY2021Q4	tsvt	Restricted Cash And Other Assets Noncurrent RestrictedCashAndOtherAssetsNoncurrent	38592000	USD
CY2022Q1	us-gaap	Assets Assets	851921000	USD
CY2021Q4	us-gaap	Assets Assets	759675000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	13647000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6024000	USD
CY2022Q1	tsvt	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	58475000	USD
CY2021Q4	tsvt	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	55410000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10066000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9769000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5000000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5000000	USD
CY2022Q1	tsvt	Collaboration Research Advancement Current CollaborationResearchAdvancementCurrent	19125000	USD
CY2021Q4	tsvt	Collaboration Research Advancement Current CollaborationResearchAdvancementCurrent	22185000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	106313000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	98388000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	25762000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	25762000	USD
CY2022Q1	tsvt	Collaboration Research Advancement Non Current CollaborationResearchAdvancementNonCurrent	710000	USD
CY2021Q4	tsvt	Collaboration Research Advancement Non Current CollaborationResearchAdvancementNonCurrent	1135000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	269289000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	272446000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2431000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2122000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	404505000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	399853000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.1000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.1000
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.1000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.1000
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37616000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37616000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23585000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23585000	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	575421000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	400026000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2804000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-712000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-125205000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39494000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	447416000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	359822000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	851921000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	759675000	USD
CY2022Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	3487000	USD
CY2021Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	1519000	USD
CY2022Q1	us-gaap	Revenues Revenues	8429000	USD
CY2021Q1	us-gaap	Revenues Revenues	11901000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69245000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	77571000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23861000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24627000	USD
CY2022Q1	tsvt	Income Loss From Collaborative Arrangements IncomeLossFromCollaborativeArrangements	-5352000	USD
CY2021Q1	tsvt	Income Loss From Collaborative Arrangements IncomeLossFromCollaborativeArrangements	0	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	511000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1704000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	48000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	369000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	99017000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	104271000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-90588000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-92370000	USD
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	115000	USD
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4762000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5174000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-85711000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-87196000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-85711000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-87196000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.20
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.20
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.73
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.73
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26751000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26751000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23369000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23369000	shares
CY2022Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2092000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2092000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-87803000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-87196000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	359822000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	165657000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9739000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2092000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-85711000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	447416000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	74629000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17109000	USD
CY2021Q1	tsvt	Transfers From Transfers To Net Parent Investment TransfersFromTransfersToNetParentInvestment	71101000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-87196000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	75643000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-85711000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-87196000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	48000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	369000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3530000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3676000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9739000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	17109000	USD
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1227000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-69000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7768000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2262000	USD
CY2022Q1	tsvt	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	4710000	USD
CY2021Q1	tsvt	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	3652000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6228000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4535000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	280000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1248000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2860000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-5639000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-820000	USD
CY2022Q1	tsvt	Increase Decrease In Collaboration Research Advancement IncreaseDecreaseInCollaborationResearchAdvancement	3487000	USD
CY2021Q1	tsvt	Increase Decrease In Collaboration Research Advancement IncreaseDecreaseInCollaborationResearchAdvancement	1519000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-74064000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-64750000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3585000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6351000	USD
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	22450000	USD
CY2021Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	70784000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	44749000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6351000	USD
CY2022Q1	us-gaap	Proceeds From Contributions From Parent ProceedsFromContributionsFromParent	0	USD
CY2021Q1	us-gaap	Proceeds From Contributions From Parent ProceedsFromContributionsFromParent	71101000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	170000000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2022Q1	tsvt	Proceeds From Stock Options Exercised And Stock Plans ProceedsFromStockOptionsExercisedAndStockPlans	99000	USD
CY2021Q1	tsvt	Proceeds From Stock Options Exercised And Stock Plans ProceedsFromStockOptionsExercisedAndStockPlans	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	170099000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	71101000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	140784000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	0	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	163266000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	304050000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	270893000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	33157000	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	304050000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2925000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1954000	USD
CY2022Q1	tsvt	Accrued Stock Issuance Costs AccruedStockIssuanceCosts	4343000	USD
CY2021Q1	tsvt	Accrued Stock Issuance Costs AccruedStockIssuanceCosts	0	USD
CY2022Q1	us-gaap	Nature Of Operations NatureOfOperations	Description of the business<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2seventy bio, Inc. (the “Company” or “2seventy bio”) was incorporated in Delaware on April 26, 2021 and is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company’s approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop highly innovative, targeted cellular therapies for patients with cancer. The Company is advancing multiple preclinical and clinical programs in oncology and, together with Bristol Myers Squibb (“BMS”), delivering the first FDA-approved CAR T therapy in multiple myeloma, ABECMA (idecabtagene vicleucel, or ide-cel), to patients in the United States. Please refer to Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative arrangements and strategic partnerships </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further discussion of the collaboration with BMS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2seventy bio Securities Corporation is a wholly-owned subsidiary of the Company which was incorporated in Massachusetts on December 13, 2021 and was granted securities corporation status in Massachusetts for the 2021 tax year. 2seventy bio Securities Corporation has no employees.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The separation from bluebird bio, Inc.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, bluebird bio, Inc. (“bluebird bio”) announced its plans to separate its oncology portfolio and programs from its severe genetic disease portfolio and programs, and spin off its oncology portfolio and programs into a separate, publicly traded company. In furtherance of this plan, on September 30, 2021, bluebird bio’s board of directors approved the distribution of all of the issued and outstanding shares of 2seventy bio common stock on the basis of one share of 2seventy bio common stock for every three shares of bluebird bio common stock issued and outstanding on October 19, 2021, the record date for the distribution. As a result of the distribution, which occurred on November 4, 2021, 2seventy bio became an independent, publicly traded company.</span></div><div style="margin-bottom:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2021, the Company also entered into a separation agreement with bluebird bio, which is referred to in this quarterly report as the separation agreement, as well as various other agreements with bluebird bio, including a tax matters agreement, an employee matters agreement, an intellectual property license agreement, a transition services agreement under which 2seventy bio temporarily receives certain services from bluebird bio, and a second transition services agreement under which 2seventy bio temporarily provides certain services to bluebird bio. These agreements also govern certain of 2seventy bio’s relationships with bluebird bio after the separation. For additional information regarding the separation agreement and the other related agreements, refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-party transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the section captioned “Transactions with Related and Certain Other Parties” in this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going concern</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated and combined financial statements are issued. The Company has incurred losses and has experienced negative operating cash flows for all historical periods presented. During the three months ended March 31, 2022, the Company incurred a net loss of $85.7 million and used $74.1 million of cash in operations. The Company expects to continue to generate operating losses and negative operating cash flows for the next few years. The Company's continued operations are dependent on its ability to raise additional funding. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company had cash, cash equivalents, and marketable securities of $452.5 million. The Company expects that its cash, cash equivalents, and marketable securities will be sufficient to fund current planned operations for at least the next twelve months from the date of issuance of these financial statements. The </span></div>Company intends to pursue additional cash resources through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances or licensing arrangements with third parties. There can be no assurance that such financing will be available in sufficient amounts or on acceptable terms, if at all, and some could be dilutive to existing stockholders. If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research or development programs or be unable to expand its operations.
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-85700000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-74100000	USD
CY2022Q1	tsvt	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	452500000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and judgments are used in the following areas, among others: allocations of revenue, expenses, assets and liabilities from bluebird bio's historical consolidated financial statements to the Company for periods prior to the separation, future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, the measurement of right-of-use assets and lease liabilities, contingent consideration, stock-based compensation expense, accrued expenses, income taxes, and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements. In addition, estimates and judgments are used in the Company’s accounting for its revenue-generating arrangements, in particular as it relates to determining the stand-alone selling price of performance obligations, evaluating whether an option to acquire additional goods and services represents a material right, estimating the total transaction price, including estimating variable consideration and the probability of achieving future potential development and regulatory milestones, assessing the period of performance over which revenue may be recognized, and accounting for modifications to revenue-generating arrangements.</span></div>
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	183817000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2164000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	181656000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	232332000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	565000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	231767000	USD
CY2022Q1	us-gaap	Interest Receivable InterestReceivable	300000	USD
CY2022Q1	tsvt	Interest Receivable Write Off InterestReceivableWriteOff	0	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	76629000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	74991000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	41591000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	40078000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35038000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34913000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14796000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	24655000	USD
CY2022Q1	tsvt	Accrued Collaboration Research Costs Current AccruedCollaborationResearchCostsCurrent	14082000	USD
CY2021Q4	tsvt	Accrued Collaboration Research Costs Current AccruedCollaborationResearchCostsCurrent	2576000	USD
CY2022Q1	tsvt	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	11097000	USD
CY2021Q4	tsvt	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	5459000	USD
CY2022Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4146000	USD
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6768000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1942000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1688000	USD
CY2022Q1	tsvt	Accrued Clinical And Contract Research Organization Costs Current AccruedClinicalAndContractResearchOrganizationCostsCurrent	1938000	USD
CY2021Q4	tsvt	Accrued Clinical And Contract Research Organization Costs Current AccruedClinicalAndContractResearchOrganizationCostsCurrent	3229000	USD
CY2022Q1	tsvt	Accrued Property Plant And Equipment Current AccruedPropertyPlantAndEquipmentCurrent	1311000	USD
CY2021Q4	tsvt	Accrued Property Plant And Equipment Current AccruedPropertyPlantAndEquipmentCurrent	2241000	USD
CY2022Q1	tsvt	Accrued Separation Related Costs Current AccruedSeparationRelatedCostsCurrent	818000	USD
CY2021Q4	tsvt	Accrued Separation Related Costs Current AccruedSeparationRelatedCostsCurrent	762000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8345000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8032000	USD
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	58475000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	55410000	USD
CY2022Q1	tsvt	Number Of Performance Obligations NumberOfPerformanceObligations	2	performance_obligation
CY2018Q3	tsvt	Number Of Accounting Units NumberOfAccountingUnits	2	accounting_unit
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9739000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17109000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9739000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17109000	USD
CY2021Q4	tsvt	Number Of Transition Services Agreements NumberOfTransitionServicesAgreements	2	agreement
CY2021Q4	tsvt	Transition Services Agreement Initial Term TransitionServicesAgreementInitialTerm	P2Y
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4470000	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares

Files In Submission

Name	View Source	Status
0001860782-22-000026-index-headers.html	Edgar Link	pending
0001860782-22-000026-index.html	Edgar Link	pending
0001860782-22-000026.txt	Edgar Link	pending
0001860782-22-000026-xbrl.zip	Edgar Link	pending
ex101firstaddendumtoheffro.htm	Edgar Link	pending
ex102secondaddendumtoheffr.htm	Edgar Link	pending
ex103-nihlicense.htm	Edgar Link	pending
ex104-nihlicenseamendment.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tsvt-20220331.htm	Edgar Link	pending
tsvt-20220331.xsd	Edgar Link	pending
tsvt-20220331_cal.xml	Edgar Link	unprocessable
tsvt-20220331_def.xml	Edgar Link	unprocessable
tsvt-20220331_htm.xml	Edgar Link	completed
tsvt-20220331_lab.xml	Edgar Link	unprocessable
tsvt-20220331_pre.xml	Edgar Link	unprocessable
tsvt-q110xqex311leschly.htm	Edgar Link	pending
tsvt-q110xqexhibit312baird.htm	Edgar Link	pending
tsvt-q1202210xqexhibit321.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TSVT
2seventy bio, Inc. Stock $tsvt

2022 Q2 Form 10-Q Financial Statement

#000186078222000026 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSVT 2seventy bio, Inc. Stock $tsvt

2022 Q2 Form 10-Q Financial Statement

#000186078222000026 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSVT
2seventy bio, Inc. Stock $tsvt